Estonia HyQvia (Human Normal Immunoglobulin (10%) and Recombinant Human Hyaluronidase) CIDP Launch 2024
Ülevaade
Kirjeldus
The Estonia CIDP Launch 2024 event is organized by Takeda and will bring together neurologists an neurophysiologists from Baltic countries and beyond. This meeting aims to explore rare immune-mediated peripheral neuropathies focusing on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and strengthen the network of key professionals in the region.
Key Highlights:
• Discussions in CIDP diagnostics and management
• Real world experience sharing with facilitated subcutaneous immunoglobulin (fSCIG)
• Focused peer-to-peer knowledge exchange
Agenda
- 14.00–15.00
- Registration and coffee
- 15.00–15.10
- Welcome – Katrin Gross-Paju, MD PhD (Estonia)
- 15.10–15.20
- Takeda commitment in Plasma-Derived Therapies (PDT)
- 15.20–15.40
- Multidisciplinary team in rare immune-mediated peripheral neuropathies – Katrin Gross-Paju, MD PhD (Estonia)
- 15.40–16.00
- Neuromuscular ultrasound (NMUS) as valuable addition to diagnostics – Assoc. Prof Liis Väli, MD PhD (Estonia)
- 16.00–16.20
- CIDP treatment – Laura Tibar, MD (Estonia)
- 16.20–16.40
- How to assess CIDP disease severity and progression? – Evelina Grušauskienė, MD (Lithuania)
- 16.40–17.00
- Coffee break
- 17.00–17.20
- CIDP treatment personalization – when treatment moves home – Lars Kjøbsted Markvardsen, MD PhD (Denmark)
- 17.20–17.40
- Practical experience with fSCIG in CIDP maintenance - dosing regimen (ramp-up), large volumes infused at once, improvement in quality of life – Lars Kjøbsted Markvardsen, MD PhD (Denmark)
- 17.40–18.00
- Patient case from Latvia – Assoc. Prof Viktorija Kenina, MD PhD (Latvia)
- 18.00–18.30
- Panel Discussion, all
- 18.30–18.35
- Closing Remarks – Katrin Gross-Paju, MD PhD (Estonia)
- 18.45–20.15
- Dinner
CIDP, Chronic Inflammatory Demyelinating Polyneuropathy; fSCIG, facilitated subcutaneous immunoglobulin.
Participating in the conference is free. To register, please fill in the online registration form down below. You should also fill in additional information to finish the registration (please include your personal e-mail address in there).
Registration is open until the 11th of November 16:00 PM.
For questions, please contact us: konverentsid@celsius.ee.
For detailed information about an individual medicinal product, please read last approved Summary of Product Characteristics.
Please read all of the Summary of Product Characteristics before prescribing HyQvia (human normal immunoglobulin 10% and recombinant human hyaluronidase) EU SmPC, May 2024 https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf.
Hospital product.
Therapeutic indications:
Replacement therapy in adults, children, and adolescents (0 to 18 years) in:
Primary immunodeficiency syndromes (PID) with impaired antibody production
Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections,ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum
IgG level of < 4 g/L.
*PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide
and polypeptide antigen vaccines.
Immunomodulatory therapy in adults, children, and adolescents (0 to 18 years) in:
Chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy afterstabilization with IVIg.
Marketing Authorisation Holder: Baxalta Innovations GmbH, Industriestrasse 67, A-1221 Vienna, Austria.
In case of any questions please contact Takeda Pharma OÜ, Järve 2, 11314 Tallinn, https://www.takeda.com/et-ee, e-mail ee.info@takeda.com, tel 617 7669
Job number: C-APROM/EE/HYQ/0034 DOP: October 2024
Meeting is initiated, organized and funded by Takeda. Only for HealthCare Professionals. Please note that all medicinal products mentioned may not be authorized/available in all countries.
Copyright 2024 Takeda Pharmaceutical Company Limited. All rights reserved